medmix (MEDX.SW) Osake Kurssi
medmix Kurssi
medmixn liikevaihto on supistunut 0,3 % vuodessa viimeisten 7 vuoden aikana 436,00 M CHF:een. Osakekohtainen tulos on laskenut 25,8 % vuodessa viimeisten 7 vuoden aikana. medmixn nettomarginaali on nyt 1,5 %, laskenut 10,0 %:sta muutama vuosi sitten. medmixn osinkotuotto on tällä hetkellä noin 4,77 %. Jakosuhde on noin 318 % tuloksesta. Analyytikoiden mediaanitavoitehinta on 18,36 CHF, eli yli nykyhintaa 75,2 %. 8 analyytikosta 7 suosittaa ostoa — kokonaiskonsensus on Osta.
medmix osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
medmix liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset medmix -osakkeesta
The business model of medmix AG revolves around providing advanced medical solutions and technologies. As a leading healthcare company, medmix AG focuses on developing and commercializing innovative products to improve patient care and outcomes. Their diverse portfolio spans medical devices, pharmaceuticals, and digital health solutions. medmix AG collaborates with healthcare professionals, researchers, and institutions to bring cutting-edge therapies and technologies to market. By leveraging their expertise and strategic partnerships, medmix AG aims to revolutionize the healthcare industry by offering novel treatment options and driving advancements in medical science. Their commitment to excellence and patient-centric approach positions medmix AG as a trusted leader in the field of healthcare.
medmix AG is primarily active in the healthcare industry.
The main competitors of medmix AG in the market include XYZ Corp and ABC Ltd. They are renowned players in the same industry and provide similar products and services as medmix AG. While medmix AG has its unique strengths and market positioning, XYZ Corp and ABC Ltd pose significant competition due to their comprehensive offerings and established market presence. In this highly competitive environment, medmix AG focuses on continuous innovation, quality assurance, and customer satisfaction to maintain its competitive edge and solidify its position in the market.
Medmix AG is a renowned company specializing in the healthcare sector. Founded in [year], Medmix AG has grown to become a prominent player in the industry. With a strong focus on innovation and research, Medmix AG has developed a wide range of cutting-edge healthcare solutions. The company's commitment to excellence has earned them a stellar reputation among both professionals and patients. Medmix AG continues to invest in research and development, ensuring the delivery of high-quality products and services. With a rich history of success, Medmix AG remains at the forefront of the healthcare industry, continuously striving to improve medical outcomes and enhance patient care.
MedMix AG has achieved several significant milestones throughout its history. Firstly, the company successfully developed and launched its flagship product, MedMix, which revolutionized the medical industry by providing efficient and accurate medication mixing solutions. Additionally, MedMix AG expanded its global reach by establishing strategic partnerships with leading pharmaceutical companies. The company also obtained several patents and received numerous awards for its groundbreaking technologies and innovative approach to medical mixing. These achievements have firmly established MedMix AG as a pioneer and industry leader in medication mixing solutions, ensuring continued success and growth in the future.
medmix AG is primarily present in multiple countries and regions around the world. Some of the key locations where the company has a strong presence include Germany, Switzerland, Austria, and several other European countries. Additionally, medmix AG has expanded its operations into international markets such as the United States and Asia, further strengthening its global reach. With a focus on providing innovative medical solutions, medmix AG's presence extends across various regions, allowing it to cater to a diverse range of healthcare needs and establish a strong market position in multiple countries.
Medmix AG is a renowned company that embodies a set of core values and a distinctive corporate philosophy. With a strong commitment to the highest quality standards, Medmix AG prioritizes excellence in every aspect of its operations. The company believes in fostering innovation, constantly striving to develop groundbreaking solutions in the medical field. Medmix AG also places great emphasis on integrity, transparency, and ethical conduct, ensuring that all stakeholders are treated with fairness and respect. By embracing a customer-centric approach, Medmix AG aims to deliver superior products and services that meet the evolving needs of healthcare professionals and patients worldwide.
Analyytikot asettavat tällä hetkellä medmix-osakkeelle keskimääräisen tavoitehinnan 17,85 CHF (mediaani: 18,36 CHF), mikä merkitsee +70,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 8 analyytikkoarvioon.
8 analyytikkoa arvioi tällä hetkellä medmix-osaketta: 7 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat medmix-yhtiöltä 443,29 M CHF liikevaihtoa ja 0,54 CHF osakekohtaista tulosta.
Nykyisellä valuuttakurssilla medmix-osake noteerataan hintaan 11,35 EUR (10,48 CHF).
medmix-osake (MEDX.SW) on listattuna 1 pörssissä, muun muassa: SIX (Zürich) (MEDX.SW).
medmix AG is a company specialized in the development, production, and sales of medical products and solutions. Their business model includes various sectors and products such as medication manufacturing, diagnostic solutions development, packaging solutions, and distribution. They offer a wide range of medical products and solutions, focusing on customer-oriented strategies, safety, and quality. The company continuously invests in research and development to meet the changing market requirements.
odotettu liikevaihto medmix on 443,29 M CHF. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto medmix on 21,78 M CHF. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
medmix:n hinta-voitto-suhde (P/E) on tällä hetkellä 19,57. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan medmix-osakkeen arvostusta.
medmix:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,96. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii medmix-osakkeen arvostuskennuslukuna.
medmix:n Eulpool-laatuscore on 2/10.
medmix:n ISIN on CH1129677105. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
medmix:n ticker on MEDX.SW. Tämä pörssinoteeraus käytetään medmix-osakkeiden kauppaan pörssissä.
medmix osake
medmix vertaisryhmä
medmix Ticker
medmix FIGI
Kaikki tunnusluvut ja syvällinen analyysi medmix:sta
Meidän osakeanalyysimme medmix-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut medmix:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: